- Previous Close
1.5800 - Open
1.6000 - Bid 1.5500 x 400
- Ask 1.5800 x 400
- Day's Range
1.5000 - 1.6037 - 52 Week Range
1.1800 - 2.6500 - Volume
131,445 - Avg. Volume
167,373 - Market Cap (intraday)
41.376M - Beta (5Y Monthly) 1.51
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1600 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.83
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
www.icadmed.comRecent News: ICAD
View More
Performance Overview: ICAD
Trailing total returns as of 9/23/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ICAD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ICAD
View MoreValuation Measures
Market Cap
41.38M
Enterprise Value
21.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.19
Price/Book (mrq)
1.34
Enterprise Value/Revenue
1.14
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-12.13%
Return on Assets (ttm)
-7.67%
Return on Equity (ttm)
-14.86%
Revenue (ttm)
18.8M
Net Income Avi to Common (ttm)
-4.54M
Diluted EPS (ttm)
-0.1600
Balance Sheet and Cash Flow
Total Cash (mrq)
20.35M
Total Debt/Equity (mrq)
1.51%
Levered Free Cash Flow (ttm)
-2.94M
Research Analysis: ICAD
View MoreCompany Insights: ICAD
ICAD does not have Company Insights